2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Vir-3434: new trials by email Literature Review of Vir-3434 trials Research Report on Vir-3434
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 150 | 2025-07-30 | 2026-07-13 |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Tobevibart, Elebsiran - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 124 | 2025-03-12 | 2026-11-03 |
Hepatitis (2) · Hepatitis D (2) · Hepatitis D, Chronic (2) · Digestive System Diseases (1) · Liver Diseases (1)
Germany (2) · Romania (2) · United Kingdom (2) · Austria (1) · Canada (1) · France (1) · Georgia (1) · Italy (1) · Moldova (1) · New Zealand (1) · Pakistan (1) · Spain (1) · Ukraine (1) · United States (1)